Neonatal systemic thrombosis: An updated overview

Gea Oliveri Conti, Angelo Claudio Molinari, Salvatore Santo Signorelli, Martino Ruggieri, Alfina Grasso, Margherita Ferrante

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Thromboembolic disease is a complex disorder with a multifactorial aetiology and a severe outcome. In newborns and children it may be missed or diagnosed late, thus worsening the prognosis. The neonatal disease is different from the disorder affecting older children and adults. However, scant epidemiological data and few randomised clinical trials regarding paediatric patients are available, and treatment recommendations are largely based on adult guidelines. Younger patients then have several decades over which they will suffer from the complications of thrombosis and risk of a new thrombotic episode. Current knowledge about neonatal thromboembolic disease and its prevention is reviewed here along with maternal, foetal, neonatal, pharmacological, environmental, lifestyle and occupational contributing factors. Additional data are urgently needed to improve diagnostic and therapeutic strategies and patient outcomes.

Original languageEnglish
Pages (from-to)499-509
Number of pages11
JournalCurrent Vascular Pharmacology
Volume16
Issue number5
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Infant, Newborn, Diseases
Thrombosis
Life Style
Randomized Controlled Trials
Mothers
Newborn Infant
Pharmacology
Guidelines
Pediatrics
Therapeutics

Keywords

  • Disease management
  • Heparin
  • Neonate
  • Risk
  • Thrombolysis
  • Thrombophilia
  • Thrombosis
  • Treatment

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

Conti, G. O., Molinari, A. C., Signorelli, S. S., Ruggieri, M., Grasso, A., & Ferrante, M. (2018). Neonatal systemic thrombosis: An updated overview. Current Vascular Pharmacology, 16(5), 499-509. https://doi.org/10.2174/1570161116666180117101445

Neonatal systemic thrombosis : An updated overview. / Conti, Gea Oliveri; Molinari, Angelo Claudio; Signorelli, Salvatore Santo; Ruggieri, Martino; Grasso, Alfina; Ferrante, Margherita.

In: Current Vascular Pharmacology, Vol. 16, No. 5, 01.01.2018, p. 499-509.

Research output: Contribution to journalReview article

Conti, GO, Molinari, AC, Signorelli, SS, Ruggieri, M, Grasso, A & Ferrante, M 2018, 'Neonatal systemic thrombosis: An updated overview', Current Vascular Pharmacology, vol. 16, no. 5, pp. 499-509. https://doi.org/10.2174/1570161116666180117101445
Conti, Gea Oliveri ; Molinari, Angelo Claudio ; Signorelli, Salvatore Santo ; Ruggieri, Martino ; Grasso, Alfina ; Ferrante, Margherita. / Neonatal systemic thrombosis : An updated overview. In: Current Vascular Pharmacology. 2018 ; Vol. 16, No. 5. pp. 499-509.
@article{71027efa318c4211821ffa1499c11792,
title = "Neonatal systemic thrombosis: An updated overview",
abstract = "Thromboembolic disease is a complex disorder with a multifactorial aetiology and a severe outcome. In newborns and children it may be missed or diagnosed late, thus worsening the prognosis. The neonatal disease is different from the disorder affecting older children and adults. However, scant epidemiological data and few randomised clinical trials regarding paediatric patients are available, and treatment recommendations are largely based on adult guidelines. Younger patients then have several decades over which they will suffer from the complications of thrombosis and risk of a new thrombotic episode. Current knowledge about neonatal thromboembolic disease and its prevention is reviewed here along with maternal, foetal, neonatal, pharmacological, environmental, lifestyle and occupational contributing factors. Additional data are urgently needed to improve diagnostic and therapeutic strategies and patient outcomes.",
keywords = "Disease management, Heparin, Neonate, Risk, Thrombolysis, Thrombophilia, Thrombosis, Treatment",
author = "Conti, {Gea Oliveri} and Molinari, {Angelo Claudio} and Signorelli, {Salvatore Santo} and Martino Ruggieri and Alfina Grasso and Margherita Ferrante",
year = "2018",
month = "1",
day = "1",
doi = "10.2174/1570161116666180117101445",
language = "English",
volume = "16",
pages = "499--509",
journal = "Current Vascular Pharmacology",
issn = "1570-1611",
publisher = "Bentham Science Publishers B.V.",
number = "5",

}

TY - JOUR

T1 - Neonatal systemic thrombosis

T2 - An updated overview

AU - Conti, Gea Oliveri

AU - Molinari, Angelo Claudio

AU - Signorelli, Salvatore Santo

AU - Ruggieri, Martino

AU - Grasso, Alfina

AU - Ferrante, Margherita

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Thromboembolic disease is a complex disorder with a multifactorial aetiology and a severe outcome. In newborns and children it may be missed or diagnosed late, thus worsening the prognosis. The neonatal disease is different from the disorder affecting older children and adults. However, scant epidemiological data and few randomised clinical trials regarding paediatric patients are available, and treatment recommendations are largely based on adult guidelines. Younger patients then have several decades over which they will suffer from the complications of thrombosis and risk of a new thrombotic episode. Current knowledge about neonatal thromboembolic disease and its prevention is reviewed here along with maternal, foetal, neonatal, pharmacological, environmental, lifestyle and occupational contributing factors. Additional data are urgently needed to improve diagnostic and therapeutic strategies and patient outcomes.

AB - Thromboembolic disease is a complex disorder with a multifactorial aetiology and a severe outcome. In newborns and children it may be missed or diagnosed late, thus worsening the prognosis. The neonatal disease is different from the disorder affecting older children and adults. However, scant epidemiological data and few randomised clinical trials regarding paediatric patients are available, and treatment recommendations are largely based on adult guidelines. Younger patients then have several decades over which they will suffer from the complications of thrombosis and risk of a new thrombotic episode. Current knowledge about neonatal thromboembolic disease and its prevention is reviewed here along with maternal, foetal, neonatal, pharmacological, environmental, lifestyle and occupational contributing factors. Additional data are urgently needed to improve diagnostic and therapeutic strategies and patient outcomes.

KW - Disease management

KW - Heparin

KW - Neonate

KW - Risk

KW - Thrombolysis

KW - Thrombophilia

KW - Thrombosis

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85049945838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049945838&partnerID=8YFLogxK

U2 - 10.2174/1570161116666180117101445

DO - 10.2174/1570161116666180117101445

M3 - Review article

C2 - 29345589

AN - SCOPUS:85049945838

VL - 16

SP - 499

EP - 509

JO - Current Vascular Pharmacology

JF - Current Vascular Pharmacology

SN - 1570-1611

IS - 5

ER -